Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies
Immatics today announced the completion of its Series E financing, raising $58 million.
Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies
4. October 2017
|In Portfolio News